Pacific Center for Financial Services’s BioCryst Pharmaceuticals BCRX Stock Holding History

Pacific Center for Financial Services’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+100	New	+$1.29K	﹤0.01%	371

Other funds holding BCRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Pacific Center for Financial Services's BCRX Position: Q3 2022 in Review

Pacific Center for Financial Services opened a new position in BioCryst Pharmaceuticals (BCRX) in Q3 2022: 100 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #371 among its holdings.

234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

Pacific Center for Financial Services held 100 shares of BioCryst Pharmaceuticals worth $1K as of Q3 2022.
BioCryst Pharmaceuticals was a new Pacific Center for Financial Services position in Q3 2022.
BioCryst Pharmaceuticals made up ﹤0.01% of Pacific Center for Financial Services's portfolio in Q3 2022, its #371 holding.
234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Pacific Center for Financial Services's 13F filing for Q3 2022, filed 14 Nov 2022.